Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan blocks AT1 receptors, preventing angiotensin II‑induced vasoconstriction. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Hydrochlorothiazide reduces sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. Together, these actions lower systemic vascular resistance and blood volume, resulting in reduced blood pressure.

The specific dose of Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva is determined by the prescribing clinician based on the patient’s blood‑pressure goals, previous therapy, and individual health status. The prescriber will select the appropriate strength and dosing schedule according to clinical guidelines and patient response.

Safety data for the combination in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk. Breastfeeding mothers should consult their healthcare provider, as the drugs may be excreted in breast milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any special handling), and assists with import documentation.

Compared with single‑agent therapies, this triple‑component tablet offers broader blood‑pressure control by targeting three complementary pathways, often reducing the need for multiple separate pills. It may be more convenient than prescribing separate ARB, calcium‑channel blocker, and diuretic tablets, but clinicians must consider individual patient tolerance, potential drug interactions, and cost when selecting therapy.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout the shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include angioedema, severe hypotension, acute renal impairment, significant electrolyte disturbances (such as hyperkalemia or hyponatremia), and hepatic dysfunction. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, fainting, or signs of kidney or liver injury.

The drug should be avoided in patients with known hypersensitivity to any of its components, severe hepatic impairment, or in those with conditions that predispose to marked hypotension. Caution is also advised for individuals with severe renal dysfunction, pregnancy, or lactation without a clear clinical justification.